Date: 2013-10-17
Type of information: Collaboration agreement
Compound: bacteriophage therapy targeting Clostridium difficile
Company: AmpliPhi BioSciences (USA - VA) Leicester University (UK)
Therapeutic area: Infectious diseases
Type agreement: collaboration licensing
Action mechanism:
Disease: Clostridium difficile infection
Details: * On October 17, 2013, AmpliPhi BioSciences Corporation, a leader in the development of bacteriophage-based antibacterial therapies to treat antibiotic resistant infections, has announced that it has entered into Collaboration and License Agreements with UK-based University of Leicester to develop a novel bacteriophage therapy targeting Clostridium difficile (C. difficile). Under the terms of the agreements, AmpliPhi will fund Dr Martha Clokie’s team at the University of Leicester to progress non-clinical studies of bacteriophage products as an alternative to treating antibiotic resistant infections caused by C. difficile bacteria. Evaluations of the efficacy of bacteriophage therapy will be carried out at the University of Glasgow, in the laboratory of Dr Gill Douce, under a three-way collaborative project between AmpliPhi, Leicester and Glasgow.
The team at the University of Leicester has discovered phages that have been shown to be effective against clinically-relevant strains of C. difficile isolated from around the world. AmpliPhi will license the patents, materials and know-how related to these discoveries from the University of Leicester and, rights, title and interest to any future intellectual property developed under this collaboration will belong to AmpliPhi. Furthermore, AmpliPhi will have exclusive rights to certain background intellectual property of the University of Leicester, for which AmpliPhi will make milestone payments based on product development and pay royalties based on product sales.
Financial terms:
Latest news:
